Evidence map›Paper›PMID 42291217›Full record

ArticleiScience2026

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Elavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, Paul V Viscuse, Xianghong Kuang, Thirukumaran Kandasamy, Dominik Awad, Jenny J Han, Licai Huang, Christine B Peterson and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Elavarasan SubramaniDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick G PiliéDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca Slack-TidwellDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul V ViscuseDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.
Xianghong KuangDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thirukumaran KandasamyDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dominik AwadDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jenny J HanDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Licai HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine B PetersonDepartment of Statistics, Rice University, Houston, TX, USA.
Amado J ZuritaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul G CornDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rama SoundararajanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter ShepherdDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Badrajee PiyarathnaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Vasanta PutluriDan L Duncan Comprehensive Cancer Center and Advanced Technology Cores, Baylor College of Medicine, Houston, TX, USA.
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Arun SreekumarDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Yuzhuo WangDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Amina ZoubeidiDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Iqbal MahmudMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sara A MartinezMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin TanMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Philip L LorenziMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sreyashi BasuImmunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sonali JindalImmunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy C ThompsonDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel E FrigoDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana M AparicioDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate CancerR01CA281727 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Timothy Charles Thompson · 2023 to 2026
$2.6M
NCI NIH HHS R01 CA281727
6 · The paper itself

Abstract

Aggressive-variant prostate cancers (AVPCs) respond poorly to anti-androgen therapy but show sensitivity to taxane-platinum chemotherapy, though outcomes remain poor. We conducted a phase 2 trial testing induction cabazitaxel plus carboplatin (CabCarb) followed by olaparib maintenance versus observation in men with AVPC. The primary endpoint of improved progression-free survival (PFS) was not met, likely due to the study being underpowered after 38.5% of patients experienced early progression (ChemoPD) prior to randomization. No genomic alterations predicted ChemoPD; however, transcriptomic analysis revealed the enrichment of metabolic pathways, including arginine metabolism, in ChemoPD tumors. These findings were supported by metabolomics data from preclinical models. In AVPC models, arginine depletion with ADI-PEG20 enhanced CabCarb efficacy

Indexed as

Health sciencesMedical specialtyMedicineOncology

Identifiers

PMID42291217
PMCPMC13254847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.